Cancer drug developer Aktis Oncology said on Thursday it priced its upsized U.S. initial public offering at $18 per share, raising about $318 million.
Aktis is targeting a valuation of up to $945.4 million in the IPO.
Related Post
Oil rises as U.S.–Venezuela tensions spark supply fears despite oversupply concerns
Oil prices climbed on Monday as supply disruptions linked to escalating U.S.-Venezuela tensions outweighed oversupply…
Vietnam Clears SpaceX’s Starlink Launch
Vietnam's government has allowed SpaceX to launch its Starlink satellite internet service in the country,…
Spirit Aviation Seeks Court Nod to Auction 20 Airbus Jets for about $500 million
Spirit Aviation Holdings is asking a U.S. bankruptcy judge in New York to approve the…